Loxiglumide, a CCK-A receptor antagonist, stimulates calorie intake and hunger feelings in humans.
Exogenous cholecystokinin (CCK) induces early satiety when infused into humans. Whether alimentary CCK (CCK-A) receptor blockade stimulates food intake in humans is, however, uncertain. The aim of the present investigation was, therefore, to establish the effect of CCK-A receptor blockade on satiety and eating behavior in healthy volunteers. To further explore the role of endogenous CCK, the effects of the specific CCK-A receptor antagonist loxiglumide (Lox; 22 micromol. kg(-1). h(-1)) on satiety and eating behavior were investigated in healthy men and compared with saline infusions (as placebo) in a series of randomized, double-blind, placebo-controlled, crossover studies. Lox produced a slight (7%), but not significant (P = 0.104), increase in food intake that was accompanied by a modest (10%), but significant (P < 0.004), increase in calorie intake. Fluid ingestion was not affected by Lox. Subjects experienced more hunger and delayed fullness during Lox infusion than during saline infusion (P < 0.05). This study provides further evidence that CCK is an endogenous physiological satiety signal acting through CCK-A receptor-mediated mechanisms. Repeated-dose studies comparing hunger and satiety responses after CCK-A receptor blockade in healthy subjects and patients with eating disorders may help clarify the possible involvement of endogenous CCK in these conditions.
Department of Research, Division of Gastroenterology, University Hospital, CH-4031 Basel, Switzerland.
C
C
Beglinger
L
L
Degen
D
D
Matzinger
M
M
D'Amato
J
J
Drewe
D000328:Adult; D018592:Cross-Over Studies; D004311:Double-Blind Method; D004327:Drinking Behavior / Q000187:drug effects / Q000502:physiology; D002149:Energy Intake / Q000187:drug effects*; D005247:Feeding Behavior / Q000187:drug effects* / Q000502:physiology; D006727:Hormone Antagonists / Q000494:pharmacology*; D006801:Humans; D006815:Hunger / Q000187:drug effects / Q000502:physiology*; D008297:Male; D011377:Proglumide / Q000031:analogs & derivatives* / Q000494:pharmacology*; D011897:Random Allocation; D043886:Receptor, Cholecystokinin A; D011949:Receptors, Cholecystokinin / Q000037:antagonists & inhibitors / Q000502:physiology*; D012016:Reference Values; D012527:Satiation / Q000187:drug effects* / Q000502:physiology
D006727:Hormone Antagonists; D043886:Receptor, Cholecystokinin A; D011949:Receptors, Cholecystokinin; C053737:loxiglumide; D011377:Proglumide